Phase I/II trial of autophagy inhibition in combination with neoadjuvant gemcitabine in patients with high-risk pancreatic adenocarcinoma: Safety, clinical response, and correlative studies

被引：3
|
作者：
Lotze, Michael T.
Boone, Brian A.
Zureikat, Amer H.
Bahary, Nathan
Lehman, David
Liotta, Lance A.
Zeh, Herbert J.
机构：
[1] Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[4] George Mason Univ, Manassas, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
    Zeh, Herbert J.
    Bahary, Nathan
    Boone, Brian A.
    Singhi, Aatur D.
    Miller-Ocuin, Jennifer Lee
    Normolle, Daniel P.
    Zureikat, Amer H.
    Hogg, Melissa E.
    Bartlett, David L.
    Lee, Kenneth K.
    Tsung, Allan
    Marsh, J. Wallis
    Murthy, Pranav
    Tang, Daolin
    Seiser, Natalie
    Amaravadi, Ravi K.
    Espina, Virginia
    Liotta, Lance
    Lotze, Michael T.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3126 - 3134
  • [32] Neoadjuvant docetaxel and capecitabine in patients (Pts) with high-risk prostate cancer (PCa): Final results of a phase II trial
    Friedman, J. D.
    Vaishampayan, U.
    Wood, D.
    Wu, A.
    Bradley, D.
    Dunn, R. L.
    Montie, J.
    Sarkar, F. H.
    Shah, R.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
    Kalbasi, Anusha
    Kamrava, Mitchell
    Chu, Fang-I
    Telesca, Donatello
    Van Dams, Ritchell
    Yang, Yingli
    Ruan, Dan
    Nelson, Scott D.
    Dry, Sarah M.
    Hernandez, Jackie
    Chmielowski, Bartosz
    Singh, Arun S.
    Bukata, Susan V.
    Bernthal, Nicholas M.
    Steinberg, Michael L.
    Weidhaas, Joanne B.
    Eilber, Fritz C.
    CLINICAL CANCER RESEARCH, 2020, 26 (08) : 1829 - 1836
  • [34] A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients
    Womble, Paul R.
    VanVeldhuizen, Peter J.
    Nisbet, Alan A.
    Reed, Greg A.
    Thrasher, J. Brantley
    Holzbeierlein, Jeffrey M.
    JOURNAL OF UROLOGY, 2011, 186 (03): : 882 - 887
  • [35] Inhibition of Autophagy Improves Pathologic and Biomarker Response to Preoperative Gemcitabine/Nab-Paclitaxel in Potentially Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial
    Miller-Ocuin, J. L.
    Bahary, N. S.
    Singhi, A. D.
    Normolle, D. P.
    Lembersky, B.
    Stoller, R.
    Sun, W.
    Ahrendt, S.
    Hogg, M.
    Lee, K.
    Bartlett, D.
    Marsh, J.
    Tsung, A.
    Zureikat, A. H.
    Boone, B. A.
    Lotze, M. T.
    Zeh, H. J.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S6 - S6
  • [36] The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study
    Watkins, D. J.
    Starling, N.
    Cunningham, D.
    Thomas, J.
    Webb, J.
    Brown, G.
    Barbachano, Y.
    Oates, J.
    Chau, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (08) : 1422 - 1429
  • [37] Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.
    Houede, Nadine
    Chevallier, Thierry
    Loic, Jaffrelot
    Thibault, Constance
    Yann, Neuzillet
    Jaillon, Christine Abraham
    Masson-Lecomte, Alexandra
    Gravis, Gwenaelle
    Tartas, Sophie
    Pouessel, Damien
    Laguerre, Brigitte
    Audenet, Francois
    Xylinas, Evanguelos
    Guillaume, Luquiens
    Roupret, Morgan
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [38] Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
    Coleman, Jonathan A.
    Yip, Wesley
    Wong, Nathan C.
    Sjoberg, Daniel D.
    Bochner, Bernard H.
    Dalbagni, Guido
    Donat, S. Machele
    Herr, Harry W.
    Cha, Eugene K.
    Donahue, Timothy F.
    Pietzak, Eugene J.
    Hakimi, A. Ari
    Kim, Kwanghee
    Al-Ahmadie, Hikmat A.
    Vargas, H. Alberto
    Alvim, Ricardo G.
    Ghafoor, Soleen
    Benfante, Nicole E.
    Meraney, Anoop M.
    Shichman, Steven J.
    Kamradt, Jeffrey M.
    Nair, Suresh G.
    Baccala, Angelo A., Jr.
    Palyca, Paul
    Lash, Bradley W.
    Rizvi, Muhammad A.
    Swanson, Scott K.
    Muina, Antonio F.
    Apolo, Andrea B.
    Iyer, Gopa
    Rosenberg, Jonathan E.
    Teo, Min Y.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) : 1618 - +
  • [39] A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Konopleva, Marina
    Kadia, Tapan M.
    Borthakur, Gautam
    Daver, Naval G.
    Durand, Mends
    Rivera, Silvia
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [40] Phase I Clinical Trial of the Combination Therapy Using Gemcitabine and GSK3beta Inhibiting Drugs for Gemcitabine-Resistant Advanced Pancreatic Cancer Patients
    Shimasaki, Takeo
    Ueda, Nobuhiko
    Kawada, Natsuko
    Nomura, Tomoe
    Yamada, Kaho
    Yamada, Hideto
    Hayashi, Ranji
    Matsunaga, Kazuhiro
    Fukuyama, Tomoki
    Otsuka, Toshimi
    Nakamura, Masakatsu
    Toshikuni, Nobuyuki
    Shiroeda, Hisakazu
    Kosaka, Takeo
    Tomosugi, Naohisa
    Minamoto, Toshinari
    Arisawa, Tomiyasu
    GASTROENTEROLOGY, 2014, 146 (05) : S387 - S387
12345